A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2011 Results will be presented on 5th February at the Late Breaking Research Symposium at the annual meeting of the American Academy of Dermatology, according to a Bavarian Nordic media release.
- 19 May 2010 Actual patient number (632) added as reported by ClinicalTrials.gov.